Author

N. Malaquin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

F. Rodier· 2 shared A.-M. Mes-Masson· 1 shared D. Provencher· 1 shared D. Tchelouggou· 1 shared G. B. Cardin· 1 shared H. Fleury· 1 shared I. Clement· 1 shared J. Bourbonnais· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Rodier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells

D. Tchelouggou, N. Malaquin, G. B. Cardin, J. Desmul, S. Turcotte, F. Rodier

This study identifies combination therapies for melanoma that enhance senolytic sensitivity by analyzing senescence responses to different treatments.

bioRxiv · Oct 1, 2023Cancer Biology

53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer

M. Skulimowski, J. Bourbonnais, N. Malaquin, H. Fleury, I. Clement, L. Communal, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that high 53BP1 levels in ovarian cancer are linked to poor survival and chemotherapy resistance, suggesting it could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology